2017
DOI: 10.1111/jcpt.12594
|View full text |Cite
|
Sign up to set email alerts
|

Acute liver failure with amiodarone infusion: A case report and systematic review

Abstract: SummaryWhat is known and objective: Amiodarone, a commonly used class III antiarrhythmic agent notable for a relatively long half-life of up to 6 months and its pronounced adverse effect profile, is used for both acute and chronic management of cardiac arrhythmias. Chronic use of amiodarone has been associated with asymptomatic hepatotoxicity; however, acute toxicity is thought to be uncommon. There are only six reported cases of acute liver failure (ALF) secondary to amiodarone. In all these cases the outcome… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
12
2
5

Year Published

2017
2017
2024
2024

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 22 publications
(19 citation statements)
references
References 19 publications
0
12
2
5
Order By: Relevance
“…Our study was neither designed nor adequately powered to discriminate hepatotoxic action of two amiodarone formulations, but some issues in our results and literature data (e.g. short duration of hospital stay until the appearance of liver injury, higher defined daily doses, significant differences in route of use between study group, known facts about possible hepatotoxicity of pharmaceutical excipients in parenteral formulation) indirectly point suggest that parenteral administration was a primary risk factor 28,29 .…”
Section: Discussionmentioning
confidence: 88%
“…Our study was neither designed nor adequately powered to discriminate hepatotoxic action of two amiodarone formulations, but some issues in our results and literature data (e.g. short duration of hospital stay until the appearance of liver injury, higher defined daily doses, significant differences in route of use between study group, known facts about possible hepatotoxicity of pharmaceutical excipients in parenteral formulation) indirectly point suggest that parenteral administration was a primary risk factor 28,29 .…”
Section: Discussionmentioning
confidence: 88%
“…Po zastosowaniu u noworodków preparatów witaminy E zawierających polisorbat 80 i polisorbat 20 obserwowano uszkodzenie wątroby z żółtaczką i niewydolnością nerek [14]. Opisano jednak przypadki, w których wystąpiło ostre uszkodzenia wątroby po dożylnym podaniu amiodaronu niezawierającego tego konserwantu [15]. Breuer i wsp.…”
Section: Patogenezaunclassified
“…Wyniki badań dodatkowych W badaniach laboratoryjnych obserwuje się zwykle zwiększoną aktywność aminotransferaz (alaninowej i asparaginianowej), wzrost stężeń bilirubiny, amoniaku i mleczanów, wydłużenie czasu protrombinowego ze wzrostem międzynarodowego współczynnika znormalizowanego (INR, international normalized ratio), małopłytkowość, hipoproteinemię oraz hipoglikemię, a w przypadku uszkodzeniu nerek podwyższenie stężeń kreatyniny i mocznika [15][16][17][18][19][20]. U chorych z cholestatycznym mechanizmem uszkodzenia wątroby obserwuje się również wzrost aktywności gamma--glutamylotransferazy i fosfatazy alkalicznej.…”
Section: Obraz Klinicznyunclassified
See 1 more Smart Citation
“…Other important side effects include corneal microdeposits, hepatic dysfunction (1-2% in intravenous use) [76,77], pulmonary fibrosis (in 5-10%), slowly progressive interstitial pneumonia with bilateral diffuse infiltrates [78,79], skin discoloration and neuropathies [71,72].…”
Section: Amiodaronementioning
confidence: 99%